{"nctId":"NCT01785095","briefTitle":"Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles","startDateStruct":{"date":"2013-03"},"conditions":["Oocyte Donation"],"count":41,"armGroups":[{"label":"FSH","type":"EXPERIMENTAL","interventionNames":["Drug: FSH (Follicle Stimulating Hormone)"]}],"interventions":[{"name":"FSH (Follicle Stimulating Hormone)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy female volunteers undergoing controlled ovarian hyperstimulation for oocyte donation with the following characteristics:\n* Able and willing to sign the Subject Consent Form and adhere to the study visit schedule;\n* \\>=18 and \\<35 years old;\n* Regular menstrual cycle (26 - 35 days);\n* BMI between 18 and 30 kg/m2;\n* First gonadotrophin treatment (i.e. naïve Subjects with regard to exposure to human derived or recombinant gonadotrophins);\n* basal FSH \\<10 IU/L and E2 \\<80 pg/ml (\\~290 pmol/l);\n* Normal TSH levels;\n* Willing to perform at least two consecutive oocyte retrieval cycles (with a wash out period of two months).\n\nExclusion Criteria:\n\n* Age \\<18 and \\>=35 years;\n* PCOS;\n* Endometriosis;\n* Subjects with evidences of autoimmune or rheumatic diseases;\n* Hypersensitivity to the active substance or to any of the excipients (lactose);\n* Abnormal bleeding of undetermined origin;\n* Subject found to be positive to anti-TSH antibodies (i.e. suffering from thyroidal diseases);\n* Uncontrolled adrenal dysfunction;\n* Neoplasia;\n* Severe impairment of renal and/or hepatic function;\n* Use of concomitant medications that might interfere with study evaluations (e.g. immunosuppressant, non-study hormonal medications, therapeutics proteins like insulin, growth hormone…).","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Producing Anti-FSH Antibodies.","description":"The immunogenicity potential of FSH in healthy volunteer will be assessed by analysing serum samples collected at different timepoints during two treatment cycle for oocytes donation: cycle 1, serum samples will be collected before treatment start (baseline), after 7-13 days and after 28 days of treatment; Cycle 2: serum samples will be collected before starting the second cycle (baseline 2), after 7-13 days and after 28 days of treatment. Cycle 1 and cycle 2 will be separated by a wash-out period of two months.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Oocytes Retrieved","description":"the number of oocytes retrieved in the first cycle and in the second cycle are compared.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":"7.7"},{"groupId":"OG001","value":"15.7","spread":"7.8"}]}]}]},{"type":"SECONDARY","title":"Total Dose of FSH Units Used.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1911.1","spread":"604.8"},{"groupId":"OG001","value":"1984.4","spread":"622.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":27},"commonTop":["Headhache","abdominal pain","Pirexia","bacterial vaginosis","candida infection"]}}}